Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs01:25

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

612
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
612
Antiasthma Drugs: Leukotriene Modifiers01:19

Antiasthma Drugs: Leukotriene Modifiers

622
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
622
Asthma-IV: Diagnostic and Management01:30

Asthma-IV: Diagnostic and Management

2.7K
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
2.7K
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

282
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
282
Antiasthma Drugs: Muscarinic Receptor Antagonists01:20

Antiasthma Drugs: Muscarinic Receptor Antagonists

599
Muscarinic receptor antagonists, also known as antimuscarinic agents, are a class of bronchodilators used to treat asthma, although they are more commonly used to treat COPD. They work by inhibiting the action of acetylcholine (ACh), a neurotransmitter, on muscarinic receptors found in the airways.
Antimuscarinic agents compete with ACh for the same binding site on the muscarinic receptors. By binding to these receptors, they inhibit the downstream effects of ACh and block the parasympathetic...
599
Asthma: Pathogenesis and Management01:20

Asthma: Pathogenesis and Management

770
Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
770

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Intraosseous Venous Malformation of the Rib With EWSR1-NFATC1 Fusion Mimicking Malignancy: A Pediatric Case Report.

Journal of pediatric hematology/oncology·2026
Same author

<i>Letter:</i> Biological Therapies for Prurigo Nodularis in Systemic Disease.

Dermatitis : contact, atopic, occupational, drug·2025
Same author

Breaking the Itch-Scratch Cycle: An Integrative Approach for Atopic Dermatitis.

Dermatitis : contact, atopic, occupational, drug·2025
Same author

Cutaneous Juvenile Xanthogranuloma With MRC1::PDGFRB Gene Fusion: A Case Report.

Pediatric dermatology·2025
Same author

A multidisciplinary Delphi consensus on the modern definition of pruritus: Sensation and disease.

Journal of the European Academy of Dermatology and Venereology : JEADV·2025
Same author

Th2 mRNA gene expression analysis separates Prurigo nodularis into two immune signature groups.

Journal of the European Academy of Dermatology and Venereology : JEADV·2025

Related Experiment Video

Updated: Sep 27, 2025

Resolving Water, Proteins, and Lipids from In Vivo Confocal Raman Spectra of Stratum Corneum through a Chemometric Approach
09:32

Resolving Water, Proteins, and Lipids from In Vivo Confocal Raman Spectra of Stratum Corneum through a Chemometric Approach

Published on: September 26, 2019

7.3K

Nemolizumab for atopic dermatitis.

Angelina Labib1, Ashley Vander Does1, Gil Yosipovitch2

  • 1Dr. Phillip Frost Department of Dermatology and Cutaneous Surgery and Miami Itch Center, University of Miami Miller School of Medicine, Miami, Florida, USA.

Drugs of Today (Barcelona, Spain : 1998)
|April 12, 2022
PubMed
Summary

Nemolizumab effectively treats atopic dermatitis (AD) by targeting Interleukin-31 (IL-31), significantly reducing itch and improving skin symptoms with a rapid onset and mild side effect profile.

Keywords:
Anti-interleukin-31 receptor α-chain (IL-31RA) agentsAtopic dermatitisDermatological disordersMonoclonal antibodiesNemolizumab

More Related Videos

Development of an Economical DNA Delivery System by "Acufection" and its Application to Skin Research
09:42

Development of an Economical DNA Delivery System by "Acufection" and its Application to Skin Research

Published on: April 19, 2017

7.5K
The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
11:39

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

Published on: July 11, 2013

39.1K

Related Experiment Videos

Last Updated: Sep 27, 2025

Resolving Water, Proteins, and Lipids from In Vivo Confocal Raman Spectra of Stratum Corneum through a Chemometric Approach
09:32

Resolving Water, Proteins, and Lipids from In Vivo Confocal Raman Spectra of Stratum Corneum through a Chemometric Approach

Published on: September 26, 2019

7.3K
Development of an Economical DNA Delivery System by "Acufection" and its Application to Skin Research
09:42

Development of an Economical DNA Delivery System by "Acufection" and its Application to Skin Research

Published on: April 19, 2017

7.5K
The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
11:39

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

Published on: July 11, 2013

39.1K

Area of Science:

  • Immunology
  • Dermatology
  • Pharmacology

Background:

  • Atopic dermatitis (AD) is a prevalent inflammatory skin condition with unmet treatment needs.
  • Interleukin-31 (IL-31) plays a key role in AD pathogenesis, driving pruritus and inflammation.
  • Emerging therapies target specific immunological pathways in AD.

Purpose of the Study:

  • To review the preclinical and clinical evidence for nemolizumab in treating AD.
  • To evaluate nemolizumab's mechanism of action, efficacy, safety, and pharmacokinetic profile.
  • To assess nemolizumab's potential as a treatment option for AD.

Main Methods:

  • Review of published preclinical and clinical studies (Phase II and III) on nemolizumab for AD.
  • Analysis of data on efficacy (pruritus, dermatitis), safety (adverse events), and pharmacokinetics.
  • Examination of the drug's mechanism targeting the IL-31 receptor alpha (IL-31RA).

Main Results:

  • Nemolizumab demonstrated significant efficacy in reducing pruritus and, to a lesser extent, dermatitis in AD patients.
  • The drug exhibits a rapid onset of action.
  • Adverse effects were generally mild and transient, with severe events being uncommon.

Conclusions:

  • Nemolizumab is a promising therapeutic agent for AD, offering significant symptom relief.
  • Its favorable efficacy, rapid action, and mild side effect profile position it as a potential first-line treatment.
  • Further investigation into its role in AD management is warranted.